saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.

Autor: Komori M; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA., Nogimori T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, 567-0085, Japan., Morey AL; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA., Sekida T; VLP Therapeutics Japan, Inc. 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo, 100-0003, Japan., Ishimoto K; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA., Hassett MR; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA., Masuta Y; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, 567-0085, Japan., Ode H; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan., Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Hokkaido, 060-8638, Japan., Suzuki R; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Hokkaido, 060-8638, Japan., Alexander J; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA., Kido Y; Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, 545-0051, Japan., Matsuda K; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA., Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Hokkaido, 060-8638, Japan., Iwatani Y; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan.; Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan., Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, 567-0085, Japan. yamamotot2@nibiohn.go.jp.; Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan. yamamotot2@nibiohn.go.jp.; Department of Virology and Immunology, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan. yamamotot2@nibiohn.go.jp., Smith JF; VLP Therapeutics, Inc. 704 Quince Orchard Rd. #110, Gaithersburg, MD, 20878, USA. jsmith@vlptherapeutics.com., Akahata W; VLP Therapeutics Japan, Inc. 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo, 100-0003, Japan. wakahata@vlptherapeutics.com.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2023 May 19; Vol. 14 (1), pp. 2810. Date of Electronic Publication: 2023 May 19.
DOI: 10.1038/s41467-023-38457-x
Abstrakt: Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal signal sequence and a C-terminal transmembrane domain (RBD-TM). Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and B-cell responses in non-human primates (NHPs). In addition, immunized hamsters and NHPs are protected against SARS-CoV-2 challenge. Importantly, RBD-specific antibodies against VOCs are maintained for at least 12 months in NHPs. These findings suggest that this saRNA platform expressing RBD-TM will be a useful vaccine candidate inducing durable immunity against emerging SARS-CoV-2 strains.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: